<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489995</url>
  </required_header>
  <id_info>
    <org_study_id>116050</org_study_id>
    <nct_id>NCT01489995</nct_id>
  </id_info>
  <brief_title>Migalastat Food Effect Study</brief_title>
  <official_title>A Randomized, Open-Label, 5-Period Crossover Study to Evaluate the Effect of Meal Type and Timing on the Pharmacokinetics of Migalastat Hydrochloride in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 5-period crossover study to evaluate the effect of meal type and timing on migalastat HCl
      pharmacokinetics in healthy male and female subjects. Subjects will be randomly assigned to 1
      of 5 treatment sequences and will receive each treatment over the course of 5 weekly periods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, open-label, 5-period crossover study to evaluate the effect of
      meal type and timing on migalastat HCl pharmacokinetics in healthy male and female subjects
      between the ages of 18 and 65 years. A total of 20 subjects will be enrolled such that
      approximately 14 evaluable subjects complete dosing and critical assessments. Subjects will
      be randomly assigned to 1 of 5 treatment sequences and will receive each treatment over the
      course of 5 successive weekly periods including a single dose of migalastat HCl 150 mg in the
      fasting state as the reference treatment. There will be at least a 7-day washout period
      between each dose of migalastat HCl and a follow-up visit approximately 7 to 10 days after
      the last dose in Period 5.

      All subjects will be screened within 28 days of admission to the clinical unit. In each
      period, subjects will check in to the clinical unit the day prior to drug administration and
      have relevant assessments to ensure continued eligibility for dose administration. On Day 1
      of each period, subjects will receive a single dose of migalastat HCl within 1 of the
      following 5 treatment regimens as follows:

        -  150 mg migalastat HCl in the fasting state (reference arm)

        -  150 mg migalastat HCl with simultaneous consumption of a glucose drink

        -  150 mg migalastat HCl 1 hour before consumption of a high fat meal

        -  150 mg migalastat HCl 1 hour before consumption of a light meal

        -  150 mg migalastat HCl 1 hour after consumption of a light meal

      Subjects will be confined to the clinical unit for 24 hours after dosing with serial blood
      samples collected for PK analysis. Safety will be assessed throughout the study by monitoring
      clinical laboratory tests, ECGs, physical examinations, vital signs, and AEs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration of migalastat HCl after a single dose</measure>
    <time_frame>5 weeks (60 PK timepoints)</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of occurence of maximum observed plasma concentration of migalastat HCl after a single dose</measure>
    <time_frame>5 weeks (60 PK timepoints)</time_frame>
    <description>tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to infinity</measure>
    <time_frame>5 weeks (60 PK timepoints)</time_frame>
    <description>AUC (0 to infinity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase half life of migalastat HCl after a single dose</measure>
    <time_frame>5 weeks (60 PK timepoints)</time_frame>
    <description>t1/2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance following oral dosing of migalastat HCl after a single dose</measure>
    <time_frame>5 weeks (60 PK timepoints)</time_frame>
    <description>CL/F</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to the time of the last quantifiable concentration</measure>
    <time_frame>5 weeks (60 PK timepoints)</time_frame>
    <description>AUC (0 to t)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose Drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Before High Fat Meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Before Light Meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After Light Meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A (migalastat)</intervention_name>
    <description>150 mg migalastat HCl in the fasting state (reference arm)</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B (migalastat)</intervention_name>
    <description>150 mg migalastat HCl with simultaneous consumption of a glucose drink</description>
    <arm_group_label>Glucose Drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C (migalastat)</intervention_name>
    <description>150 mg migalastat HCl 1 hour before consumption of a high fat meal</description>
    <arm_group_label>Before High Fat Meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D (migalastat)</intervention_name>
    <description>150 mg migalastat HCl 1 hour before consumption of a light meal</description>
    <arm_group_label>Before Light Meal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E (migalastat)</intervention_name>
    <description>150 mg migalastat HCl 1 hour after consumption of a light meal</description>
    <arm_group_label>After Light Meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female aged 18 to 65 years inclusive

          -  Healthy, as determined by study physician

          -  Capable of giving informed consent

        Exclusion Criteria:

          -  Positive for HIV or Hepatitis B and/or C viruses

          -  History of drug or alcohol abuse or addiction within 2 years

          -  Smoker or consumes tobacco products

          -  Participation in a clinical trial within 30 days of scheduled first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>AmicusTherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food effect</keyword>
  <keyword>GR181413A</keyword>
  <keyword>AT1001</keyword>
  <keyword>migalastat hydrochloride</keyword>
  <keyword>Lysosomal storage disorders</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1-Deoxynojirimycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

